Nimotuzumab (poeder)

Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a KD value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) [1][2].

780758-10-3

12352203

EGFR

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Cancer-Kinase/protease

Cancer

[Nimotuzumab(powder)]

(147.58 kDa)

[1]Zaima Mazorra, et al. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Front Pharmacol. 2017 Jun 19;8:382.|[2]Melarkode S Ramakrishnan, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. Jan-Feb 2009;1 (1) :41-8.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P9968A/

Inhibitory Antibodies

No Development Reported